Physician

Ashish Manne, MBBS

According to 2025 Medicare claims, Ashish Manne, MBBS (NPI: 1811303001) practices medical oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is OSU INTERNAL MEDICINE, LLC (NPI: 1740231448; TIN: 311369596) and primary practice location at 43221-3502. Manne is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Manne's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 129 traditional Medicare patients, billed 323 HCPCS/CPT codes, and received $29,693 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 95 prescription claims across 33 beneficiaries totaling $458,752 in drug costs, led by Lonsurf (Trifluridine/Tipiracil Hcl). DME data shows 58 claims. Open Payments data shows 59 records totaling $397,889. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $4,532 to $29,693. Similarly, Part D prescription costs have moved sharply higher in recent years, from $26,270 to $458,752. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	27	51	$4,532
2018	69	117	$9,341
2019	N/R	N/R	N/R
2020	51	141	$13,331
2021	123	471	$47,628
2022	127	439	$44,973
2023	140	388	$35,718
2024	129	323	$29,693

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	58	441	$26,270
2016	43	326	$21,893
2017	32	159	$8,025
2018	18	46	$754
2019	22	57	$4,376
2020	20	39	$26,901
2021	28	66	$295,296
2022	39	93	$400,956
2023	37	117	$484,414
2024	33	95	$458,752

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	40	$3,697
2022	N/R	38	$1,745
2023	N/R	N/R	N/R
2024	N/R	58	$1,804

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	45	45	$131
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	55	129	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	58	95	$67
99442	Telephone medical discussion with physician, 11-20 minutes	14	15	$50

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lonsurf	Trifluridine/Tipiracil Hcl	13	364	$155,773

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	28	$1,327
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$344	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	55	$397,546	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ashish Manne, MBBS?

Tedicare shows public-source Medicare data for Ashish Manne, MBBS (NPI 1811303001), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ashish Manne, MBBS have ACO affiliation data?

Ashish Manne, MBBS is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Ashish Manne, MBBS?

Ashish Manne, MBBS is linked to OSU INTERNAL MEDICINE, LLC (billing NPI 1740231448) in the available physician profile data.

Does Ashish Manne, MBBS have Open Payments data?

Ashish Manne, MBBS has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.